07:00 , May 14, 2012 |  BC Week In Review  |  Financial News

Retrophin completes venture financing

Retrophin LLC , New York, N.Y.   Business: Renal, Musculoskeletal, Pulmonary   Date completed: 5/7/12   Type: Venture financing   Raised: $4 million   Investors: MSMB Capital; individual investors  ...
08:00 , Feb 20, 2012 |  BC Week In Review  |  Company News

SeraCare deal

Private equity firm Linden Capital Partners will acquire SeraCare for $4 per share, or about $80.8 million based on 20.2 million shares outstanding on Feb. 3. The price is a 12% premium to SeraCare's close...
07:00 , Oct 24, 2011 |  BC Week In Review  |  Clinical News

Lymphoseek tilmanocept regulatory update

FDA accepted for review an NDA from Neoprobe for Lymphoseek tilmanocept for use in intraoperative lymphatic mapping (ILM). The NDA for theTc99m-labeled radioactive tracing agent was submitted on Aug. 10. A standard 10-month review would...
07:00 , Oct 17, 2011 |  BC Week In Review  |  Company News

Allos, AMAG Pharmaceuticals deal

Allos said an undisclosed company withdrew an offer to acquire Allos for $2.20 per share, or about $232 million. Last month, Allos said it was in negotiations with the company (see BioCentury, Sept. 26). Allos...
07:00 , Oct 17, 2011 |  BioCentury  |  Finance

Accept / reject / reset

Proxy advisory firm Institutional Shareholder Services Inc. made clear who it thinks is getting the better end of the proposed merger between AMAG Pharmaceuticals Inc. and Allos Therapeutics Inc. Last week, ISS released a pair...
07:00 , Sep 19, 2011 |  BC Week In Review  |  Company News

Allos deal

The unsolicited offer, made on Sept. 2, is a 22% premium to Allos' close of $1.64 on that day. The offer is a 3% discount to Allos' close of $2.06 on July 19, before Allos...
00:23 , Sep 15, 2011 |  BC Extra  |  Company News

Allos rejects unsolicited offer, maintains AMAG merger plans

Allos Therapeutics Inc. (NASDAQ:ALTH) rejected an undisclosed company's offer to acquire Allos in a cash and stock deal that valued the cancer company at $2 per share, or about $211 million. The details were revealed...
07:00 , Aug 15, 2011 |  BC Week In Review  |  Clinical News

Lymphoseek tilmanocept regulatory update

Neoprobe submitted an NDA to FDA for Lymphoseek tilmanocept for use in intraoperative lymphatic mapping. Lymphoseek is a Tc99m-labeled radioactive tracing agent. In June, Neoprobe filed a formal response to a June 2 Citizen's Petition...
07:00 , Aug 15, 2011 |  BC Week In Review  |  Company News

AMAG Pharmaceuticals, MSMB Capital Management LLC deal

AMAG said its board unanimously rejected an unsolicited offer from shareholder MSMB Capital to acquire AMAG for $18 per share, or about $380.9 million in cash. AMAG said its board determined that MSMB's proposal "is...
07:00 , Aug 15, 2011 |  BioCentury  |  Finance

Rebalancing act

Companies in the midst of launching products or with weak balance sheets have been sold off or avoided by most investors during the market roller-coaster of the past two weeks. However, a handful of companies...